German generic drugmaker Stada has agreed to a shareholder vote on proposed board changes after an activist investor had asked for a thorough overhaul, the company said on Friday.
Active Ownership Capital will now seek to replace three instead of five of Stada’s nine supervisory board members at its annual general meeting on June 9, and it is no longer asking for the removal of board Chairman Martin Abend.
Stada said in a statement it was agreeing to the compromise to avoid a pricey legal battle as well as the need to call an extraordinary meeting of shareholders.
Shares in Stada have surged about 11 percent this month on speculation that Active Ownership’s campaign could lead to the sale or break up of the company.
The Luxembourg-based investor, which has a 5 percent stake in the company, has said its push for a shareholder vote on the supervisory board is to add international healthcare expertise to help Stada realise its potential.
Active Ownership wants Klaus-Joachim Krauth, the former finance chief of Hexal and Athos; Ulrich Wandschneider, who until recently was chief executive of hospitals chain Asklepios Kliniken; and Active Ownership founding partner Klaus Roehrig on the supervisory board.
They would replace Eckhard Brueggemann, Arnold Hertzsch and Constantin Meyer.
By Arno Schuetze, Alexander Huebner and Maria Sheahan
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
